AZTA — Azenta, Inc.

Summary of Azenta's Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $145 million, up 1% year-over-year; down 3% organically when excluding foreign exchange and the UK Biocentre acquisition.
• Adjusted EBITDA Margin: 5.4%, a decline of 320 basis points year-over-year, primarily due to lower volumes and increased costs.
• Non-GAAP EPS: Loss of $0.04 per share.
• Free Cash Flow: $5 million, supported by improved working capital.
• Cash Position: $565 million in cash and equivalents, with no debt outstanding.

2. Strategic Updates and Business Highlights

• Multiomics Growth: Continued strength in Europe and Asia, but North America faced softer demand and competitive pressure.
• Sample Management Solutions: Strong growth in sample repository solutions, but overall performance impacted by lower capital spending on automated and cryogenic systems.
• Operational Improvements: Significant enhancements in on-time delivery from 15% to 70% in consumables and instruments; reduced turnaround time for Lightning RNA-Seq from 20 days to 5 days.
• Leadership Changes: Appointment of Trey Martin as President of the Multiomics business to drive transformation and improve commercial execution.
• Acquisition of UK Biocentre: Integration is progressing as planned, enhancing Azenta's presence in the UK and Europe.

3. Forward Guidance and Outlook

• Revised Fiscal 2026 Guidance:
  • Total revenue expected between $603 million and $621 million.
  • Organic revenue forecasted to decline 2% to grow 1%, down from previous expectations of 3% to 5% growth.
  • Adjusted EBITDA margin anticipated to decline approximately 125 basis points to flat year-over-year.
• Segment Expectations:
  • Sample Management Solutions expected to grow low single digits organically.
  • Multiomics projected to decline mid-single digits.
• Long-Range Plan: Pushed out by one year to 2029, maintaining the same financial targets.

4. Bad News, Challenges, or Points of Concern

• Execution Shortfalls: Noted internal execution issues impacting performance, particularly in North America.
• Declining Metrics: Organic revenue down 3%, with a significant decline in Multiomics driven by lower volumes and competitive pressure.
• Quality Issues: Ongoing remediation of automated storage systems, with three remaining stores experiencing delays.
• Market Environment: Cautious demand environment in North America, particularly affecting customer spending and research funding.
• Goodwill Impairments: Noncash impairment charges of $112.4 million for Multiomics and $36.6 million for Sample Management Solutions due to decreased stock price and outlook.

5. Notable Q&A Insights

• Cadence of Performance: Q2 saw improved bookings early on, but a lack of expected demand spike in the third month led to disappointing results.
• Competitive Dynamics: Increased competition in North America, particularly in gene synthesis, impacting revenue.
• Human Capital Challenges: Rebuilding of the sales team in North America has created execution gaps, but new leadership is expected to drive improvements.
• B Medical Systems Update: Ongoing financing delays for the acquisition, with no current timeline for resolution, but confidence remains in closing the deal.
• Future Focus: Emphasis on balancing gene synthesis and sequencing capabilities, with plans to leverage AI and bioinformatics in future strategies.

Overall, Azenta is navigating a challenging environment with strategic initiatives aimed at improving execution and operational efficiency while addressing internal and external pressures.